Mumbai: Bristol Myers Squibb is positioning India as a key growth engine as the US biopharma major enters one of its most active pipeline phases and looks to reshape pharmaceutical commercialisation harnessing artificial intelligence. BMS, which grossed over $48 billion in sales last year, expects multiple global data readouts over the next 12-18 months across…
Armed with positive results in two phase 3 trials, Takeda intends to file for approval of its oral psoriasis therapy zasocitinib in the US and other countries next year, with Bristol Myers Squibb’s Sotyktu in its sights. Once-daily zasocitinib, described as a second-generation TYK2 inhibitor, met all its safety and efficacy objectives in patients with…
Eli Lilly has ramped up the competition in weight-loss therapies by reporting the first pivotal data with its triple therapy retatrutide, showing average weight losses of up to 28.7% in its first phase 3 readout. Top-line results from the TRIUMPH-4 trial, carried out in patients overweight or with obesity and knee osteoarthritis, raise expectations for…
Swiss biotech AC Immune has said that its vaccine-like alpha-synuclein-targeted immunotherapy has shown promise in slowing down the progression of Parkinson’s disease. The results of the phase 2 VacSYn trial of ACI-7104.056 in patients with early-stage Parkinson’s have shown that the immunotherapy can reduce disease-related biomarkers – namely alpha-synuclein levels in the cerebrospinal fluids (CSF)…
Pfizer’s oral HER2 inhibitor Tukysa looks poised to find a new role as first-line maintenance therapy for HER2-positive metastatic breast cancer, based on now-revealed data from the HER2CLIMB-05 study. The results, presented at the SABCS conference, show that the combination of Tukysa (tucatinib), trastuzumab, and pertuzumab reduced the risk of disease progression or death by…
Shares in Praxis Medicines rose more than 28% today after the company said it was halting a trial of its experimental therapy for rare childhood epilepsies early and preparing to file for approval. The EMBOLD study of relutrigine (also known as PRAX-562) was testing the oral drug in patients with SCN2A and SCN8A developmental and…
Participation of the incarcerated in Clinical Trials in India: Need for a road map -Albina Arjuman We use cookies for analytics, advertising and to improve our site. You agree to our use of cookies by continuing to use our site. To know more, see our Cookie Policy and Cookie Settings.Ok Source link
Bayer has started a phase 2a trial of an antibody that it hopes could provide a targeted, potentially disease-modifying therapy for Alport syndrome, a rare, genetic disease that leads to chronic kidney disease (CKD). Alport is caused by mutations in genes that are involved in the formation of type IV collagen, a protein integral to…
Belite Bio has said the results of the DRAGON trial of its oral therapy for sight-robbing disorder Stargardt disease type 1 (STGD1), tinlarebant, could support an FDA filing. The San Diego biotech said that DRAGON is the first successful pivotal trial in patients with STGD1, an eye disease that leads to progressive vision loss, usually…
A real-world study exploring the long-term effects of Eli Lilly’s weight-loss therapy tirzepatide in primary care settings has started in the UK. The five-year SURMOUNT-REAL UK trial, part of a collaboration signed last year between Lilly and the UK government, will chart the effects of tirzepatide on weight loss, diabetes prevention, and the prevention of…